GRECCAR 8: Primary Tumor Resection in Rectal Cancer With Unresectable Metastasis

Inclusion Criteria:

* Non-complicated primary tumor (i.e. tumor without obstruction, bleeding, abscess or perforation requiring emergency surgery and/or contra-indicating first-line chemotherapy)
* Unresectable synchronous metastases
* ECOG performance status 0-1
* Rectal adenocarcinoma (\<15 cm from the anal verge) with few or no symptoms and unresectable metastasis (assessed by the investigator) unsuitable for curative treatment
* No known unresectable primary tumor (with clear margin \>1mm) on CT-scan and MRI
* No disease progression under chemotherapy (for at least 4 cycles);
* Assessment of KRAS status before randomization (wild type or mutated);
* Life expectancy without cancer \>2 years
* White blood cell count ≥ 3 x 109/L, with neutrophils ≥ 1,5 x 109/L, platelet count ≥ 100 x 109/L, hemoglobin°≥ 9 g/dL (5,6 mmol/l)
* Total bilirubin ≤ 1.5 x ULN (upper limit of normal), ASAT and ALAT ≤ 2.5 x ULN, alkaline phosphatase°≤°1.5°x ULN, serum creatinine ≤ 1.5 x ULN;
* Age ≥ 18 years ≤ 75 years
* Patients with childbearing potential should use effective contraception during the study and up 6 months after the end of chemotherapy
* Covered by a Health System where applicable, and/or in compliance with the recommendations of the national laws in force relating to biomedical research;
* Signed written informed consent obtained prior to any study-specific screening procedures

Exclusion Criteria:

* Rectal tumor operated before inclusion
* Symptoms related to the rectal tumor requiring first intention rectal surgery (appreciated by investigator)
* Contra-indication for surgery
* Resectable metastases
* Complicated (obstruction, bleeding, abscess, perforation) primary tumor requiring emergency surgery and/or contra-indicating first line-chemotherapy
* Non-resectable primary tumor (with wild margin)
* Age \> 75 years \< 18 years
* ECOG performance status \> 2
* Under nutrition (albumin \< 30 g/l)
* Peritoneal carcinomatosis
* Disease progression under chemotherapy (RECIST 1.1 criteria)
* Known hypersensitivity reaction or specific contraindications to any of the components of study treatments
* Clinically relevant coronary artery disease or history of myocardial infarction in the last 12 months, or high risk of uncontrolled arrhythmia
* Pregnancy (absence to be confirmed by ß-hCG test) or breast-feeding;
* Previous malignancy in the last 5 years
* Medical, geographical, sociological, psychological or legal conditions that would prevent the patient from completing the study or signing the informed consent; in the investigator's opinion
* Any significant disease which, in the investigator's opinion, excludes the patient from the study
* Under an administrative or legal supervision.